Table 2.
Univariate and multivariate cox progression of OS and BCSS of breast cancer patients with initial bone metastasis.
| Overall survival | Breast cancer-specific survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Age | ||||||||
| <60 | Reference | Reference | ||||||
| ≥60 | 1.40(1.31–1.49) | <0.001 | 1.43(1.33–1.52) | <0.001 | 1.32(1.24–1.41) | <0.001 | 1.36(1.27–1.45) | <0.001 |
| Sex | ||||||||
| Female | Reference | Reference | ||||||
| Male | 1.15(0.88–1.51) | 0.302 | / | / | 1.11(0.83–1.48) | 0.479 | / | / |
| Race | ||||||||
| White | Reference | Reference | ||||||
| Black | 1.42(1.31–1.54) | <0.001 | 1.27(1.16–1.38) | <0.001 | 1.41(1.29–1.53) | <0.001 | 1.24(1.13–1.35) | <0.001 |
| Other | 0.92(1.81–1.04) | 0.172 | 0.93(0.82–1.05) | 0.244 | 0.95(0.83–1.08) | 0.432 | 0.95(0.84–1.09) | 0.465 |
| Unknown | 0.15(0.02–1.08) | 0.059 | 0.11(0.01–0.75) | 0.025 | 0.16(0.02–1.17) | 0.071 | 0.12(0.02–0.83) | 0.031 |
| Grade | ||||||||
| I | Reference | Reference | ||||||
| II | 1.28(1.11–1.48) | 0.001 | 1.30(1.12–1.50) | <0.001 | 1.33(1.14–1.55) | <0.001 | 1.34(1.14–1.56) | <0.001 |
| III | 1.81(1.57–2.09) | <0.001 | 1.75(1.51–2.03) | <0.001 | 1.95(1.68–2.27) | <0.001 | 1.86(1.59–2.17) | <0.001 |
| IV | 4.04(2.62–6.21) | <0.001 | 2.42(1.57–3.74) | <0.001 | 4.64(3.01–7.15) | <0.001 | 2.75(1.78–4.27) | <0.001 |
| Unknown | 1.72(1.47–2.01) | <0.001 | 1.42(1.21–1.66) | <0.001 | 1.81(1.53–2.14) | <0.001 | 1.49(1.25–1.76) | <0.001 |
| Subtype | ||||||||
| HR+/HER2- | Reference | Reference | ||||||
| HR+/HER2+ | 0.80(0.73–0.88) | <0.001 | 0.65(0.59–0.72) | <0.001 | 0.82(0.75–0.91) | <0.001 | 0.65(0.59–0.72) | <0.001 |
| HR-/HER2+ | 0.98(0.86–1.13) | 0.8 | 0.74(0.64–0.86) | <0.001 | 1.02(0.88–1.17) | 0.832 | 0.74(0.64–0.85) | <0.001 |
| HR-/HER2- | 2.94(2.67–3.23) | <0.001 | 2.51(2.27–2.78) | <0.001 | 3.03(2.74–3.34) | <0.001 | 2.54(2.28–2.82) | <0.001 |
| T | ||||||||
| 1 | Reference | Reference | ||||||
| 2 | 0.98(0.88–1.10) | 0.721 | 1.04(0.93–1.16) | 0.527 | 0.96(0.85–1.07) | 0.458 | 1.01(0.90–1.13) | 0.893 |
| 3 | 1.19(1.05–1.34) | 0.005 | 1.19(1.05–1.34) | 0.005 | 1.19(1.05–1.35) | 0.006 | 1.19(1.05–1.35) | 0.008 |
| 4 | 1.49(1.33–1.66) | <0.001 | 1.27(1.14–1.42) | <0.001 | 1.48(1.33–1.66) | <0.001 | 1.26(1.12–1.41) | <0.001 |
| N | ||||||||
| 0 | Reference | Reference | ||||||
| 1 | 0.97(0.89–1.05) | 0.464 | / | / | 0.99(0.91–1.08) | 0.829 | / | / |
| 2 | 0.97(0.87–1.08) | 0.607 | / | / | 0.98(0.87–1.10) | 0.702 | / | / |
| 3 | 1.03(0.93–1.14) | 0.618 | / | / | 1.06(0.95–1.18) | 0.287 | / | / |
| Marital status | ||||||||
| Married | Reference | Reference | ||||||
| Unmarried | 1.36(1.27–1.45) | <0.001 | 1.23(1.15–1.32) | <0.001 | 1.33(1.24–1.42) | <0.001 | 1.21(1.13–1.30) | <0.001 |
| Unknown | 1.11(0.95–1.30) | 0.17 | 1.05(0.90–1.23) | 0.546 | 1.14(0.97–1.33) | 0.113 | 1.07(0.91–1.26) | 0.396 |
| Insurance | ||||||||
| Insured | Reference | Reference | ||||||
| Uninsured | 1.27(1.09–1.48) | 0.002 | 1.20(1.03–1.40) | 0.021 | 1.34(1.14–1.56) | <0.001 | 1.26(1.07–1.47) | 0.004 |
| Unknown | 0.96(0.73–1.25) | 0.744 | 0.89(0.67–1.17) | 0.393 | 0.98(0.75–1.3) | 0.902 | 0.90(0.68–1.20) | 0.480 |
| Brain involvement | ||||||||
| No | Reference | Reference | ||||||
| Yes | 2.31(2.07–2.59) | <0.001 | 1.83(1.63–2.05) | <0.001 | 2.37(2.12–2.66) | <0.001 | 1.85(1.64–2.08) | <0.001 |
| Liver involvement | ||||||||
| No | Reference | Reference | ||||||
| Yes | 1.83(1.71–1.97) | <0.001 | 1.68(1.56–1.82) | <0.001 | 1.93(1.79–2.08) | <0.001 | 1.75(1.62–1.90) | <0.001 |
| Lung involvement | ||||||||
| No | Reference | Reference | ||||||
| Yes | 1.60(1.5–1.72) | <0.001 | 1.22(1.14–1.32) | <0.001 | 1.62(1.50–1.74) | <0.001 | 1.22(1.13–1.32) | <0.001 |
| Surgery | ||||||||
| No | Reference | Reference | ||||||
| Yes | 0.56(0.5–0.60) | <0.001 | 0.60(0.56–0.65) | <0.001 | 0.56(0.52–0.60) | <0.001 | 0.60(0.56–0.65) | <0.001 |
HR, hormone receptor; HER2, human epidermal growth factor 2; AJCC, American Joint Committee on Cancer; CI, confidence interval.